Polyrizon (NASDAQ:PLRZ) Stock Price Up 1.1% – Still a Buy?

Polyrizon Ltd. (NASDAQ:PLRZ)’s share price traded up 1.1% on Thursday . The stock traded as high as $14.25 and last traded at $13.61. 38,622 shares traded hands during mid-day trading, a decline of 14% from the average session volume of 44,875 shares. The stock had previously closed at $13.46.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Polyrizon in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has a consensus rating of “Sell”.

Polyrizon Price Performance

The business has a 50-day simple moving average of $13.30 and a 200-day simple moving average of $9.02.

Hedge Funds Weigh In On Polyrizon

A hedge fund recently bought a new stake in Polyrizon stock. Jane Street Group LLC purchased a new position in shares of Polyrizon Ltd. (NASDAQ:PLRZ) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 14,032 shares of the company’s stock, valued at approximately $119,000. Jane Street Group LLC owned 1.35% of Polyrizon at the end of the most recent reporting period.

About Polyrizon

Polyrizon Ltd. is a development stage biotech company specializing in the development of medical device hydrogels delivered in the form of nasal sprays. Polyrizon Ltd. is based in Raanana, Israel.